News

News Subscription

Sep 13. 2013
Basilea reports presentation of 19 posters at ICAAC on investigational anti-infectives isavuconazole, ceftobiprole, and BAL30072
Read more
Download
Aug 21. 2013
Basilea reports 2013 half-year financials with improved operating results
Read more
Download
Jul 17. 2013
Basilea provides update on isavuconazole phase 3 program
Read more
Download
Jun 25. 2013
Basilea awarded contract by BARDA of up to USD 89 million for the development of its novel antibiotic BAL30072
Read more
Download
Jun 04. 2013
Basilea presents first phase 1 data from its novel anti-cancer drug BAL101553 at ASCO conference
Read more
Download
May 28. 2013
Basilea reports isavuconazole orphan drug designation by U.S. FDA
Read more
Download
Apr 29. 2013
Basilea reports presentation of new data on anti-infective drug candidates addressing drug resistance
Read more
Download
Apr 09. 2013
Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
Read more
Download
Mar 07. 2013
Basilea's Board proposes Martin Nicklasson to succeed Chairman Werner Henrich and recommends to shareholders that they do not support the request for a capital distribution at this time
Read more
Download
Feb 23. 2013
Basilea receives request to place repayment of CHF 48 million from capital contribution reserve on the agenda of the ordinary general meeting of shareholders
Read more
Download